Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
Chi KN, Armstrong AJ, Krause BJ, Herrmann K, Rahbar K, de Bono JS, Adra N, Garje R, Michalski JM, Kempel MM, Fizazi K, Morris MJ, Sartor O, Brackman M, DeSilvio M, Wilke C, Holder G, Tagawa ST. Chi KN, et al. Among authors: garje r. Eur Urol. 2024 Apr;85(4):382-391. doi: 10.1016/j.eururo.2023.12.004. Epub 2024 Jan 6. Eur Urol. 2024. PMID: 38185538 Free article. Clinical Trial.
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target across Human Malignancies.
Miller CD, Lozada JR, Zorko NA, Elliott A, Makovec A, Radovich M, Heath EI, Agarwal N, McKay RR, Garje R, Bastos BR, Hoon DS, Orme JJ, Sartor O, Vanderwalde A, Nabhan C, Sledge GW, Shenderov E, Dehm SM, Lou E, Miller JS, Hwang JH, Antonarakis ES. Miller CD, et al. Among authors: garje r. Cancer Res Commun. 2024 May 6. doi: 10.1158/2767-9764.CRC-23-0546. Online ahead of print. Cancer Res Commun. 2024. PMID: 38709075 Free article.
Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.
Park JJ, Chu A, Li J, Ali A, McKay RR, Hwang C, Labriola MK, Jang A, Kilari D, Mo G, Ravindranathan D, Graham LS, Sokolova A, Tripathi A, Pilling A, Jindal T, Ravindra A, Cackowski FC, Sweeney PL, Thapa B, Amery TS, Heath EI, Garje R, Zakharia Y, Koshkin VS, Bilen MA, Schweizer MT, Barata PC, Dorff TB, Cieslik M, Alva AS, Armstrong AJ. Park JJ, et al. Among authors: garje r. JCO Precis Oncol. 2024 Apr;8:e2300567. doi: 10.1200/PO.23.00567. JCO Precis Oncol. 2024. PMID: 38579192
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.
Zengin ZB, Henderson NC, Park JJ, Ali A, Nguyen C, Hwang C, Barata PC, Bilen MA, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin VS, Patel VG, Schweizer MT, Armstrong AJ, McKay RR, Alva A, Dorff T. Zengin ZB, et al. Among authors: garje r. Prostate Cancer Prostatic Dis. 2024 Feb 22. doi: 10.1038/s41391-024-00805-3. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38383885
Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
Hwang C, Henderson NC, Chu SC, Holland B, Cackowski FC, Pilling A, Jang A, Rothstein S, Labriola M, Park JJ, Ghose A, Bilen MA, Mustafa S, Kilari D, Pierro MJ, Thapa B, Tripathi A, Garje R, Ravindra A, Koshkin VS, Hernandez E, Schweizer MT, Armstrong AJ, McKay RR, Dorff TB, Alva AS, Barata PC. Hwang C, et al. Among authors: garje r. JAMA Netw Open. 2023 Sep 5;6(9):e2334208. doi: 10.1001/jamanetworkopen.2023.34208. JAMA Netw Open. 2023. PMID: 37721753 Free PMC article.
Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration.
Dorff T, Zengin Z, Henderson N, Ali A, Nguyen C, Hwang C, Barata PC, Bilen M, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A. Dorff T, et al. Among authors: garje r. Res Sq [Preprint]. 2023 Aug 10:rs.3.rs-3201150. doi: 10.21203/rs.3.rs-3201150/v1. Res Sq. 2023. PMID: 37609284 Free PMC article. Updated. Preprint.
Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Q and A.
Garje R, Hope TA, Rumble RB, Parikh RA; Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer Guideline Expert Panel. Garje R, et al. JCO Oncol Pract. 2023 Mar;19(3):132-135. doi: 10.1200/OP.22.00753. Epub 2023 Jan 24. JCO Oncol Pract. 2023. PMID: 36693228 No abstract available.
46 results